AUPH News and Press, Aurinia Pharmaceuticals Inc From 03/16/21

This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS™ (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in multiple upcoming investor conferences including the: Cowen 41 st Annual virtual Healthcare Conference firesid...

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Aurinia Pharmaceuticals Inc. 2020 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transc...

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2020 Earnings Conference Call February 24, 2021 16:30 ET Company Participants Glenn Schulman - Senior Vice President, Investor Relations Peter Greenleaf - President and Chief Executive Officer Neil Solomons - Chief Medical Officer Max Colao - Chief Comme...

Aurinia Pharma (AUPH): Q4 GAAP EPS of -$0.05 beats by $0.15.Revenue of $50.03M (+166666.7% Y/Y) beats by $37.49M.Cash, cash equivalents, and investments of $423M at December 31, 2020.Shares +1.13%.Press Release For further details see: Aurinia Pharma EPS beats by $0.15, beats on revenue...

- LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - Cash, cash equivalents, and investments of $423 million at December...

We propose a method for selling options that defies many myths around options selling. We analyzed options prices using statistical modelling and calculus to improve the "expected value" of trading versus conventional principles. Trades based on the criteria below are likely to wi...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 202...